DE69813620D1 - Verwendung von citrullin enthaltenden peptiden, die von filaggrin abstammen, zur behandlung von autoimmunkrankheiten - Google Patents

Verwendung von citrullin enthaltenden peptiden, die von filaggrin abstammen, zur behandlung von autoimmunkrankheiten

Info

Publication number
DE69813620D1
DE69813620D1 DE69813620T DE69813620T DE69813620D1 DE 69813620 D1 DE69813620 D1 DE 69813620D1 DE 69813620 T DE69813620 T DE 69813620T DE 69813620 T DE69813620 T DE 69813620T DE 69813620 D1 DE69813620 D1 DE 69813620D1
Authority
DE
Germany
Prior art keywords
filaggrin
citrullin
treatment
autoimmune diseases
containing peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69813620T
Other languages
English (en)
Other versions
DE69813620T2 (de
Inventor
Guy Serre
Elisabeth Girbal-Neuhauser
Christian Vincent
Michel Simon
Mireille Sebbag
Pascal Dalbon
Colette Jolivet-Reynaud
Michel Arnaud
Michel Jolivet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Toulouse III Paul Sabatier
Original Assignee
Universite Toulouse III Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Toulouse III Paul Sabatier filed Critical Universite Toulouse III Paul Sabatier
Application granted granted Critical
Publication of DE69813620D1 publication Critical patent/DE69813620D1/de
Publication of DE69813620T2 publication Critical patent/DE69813620T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
DE69813620T 1997-12-30 1998-12-29 Verwendung von citrullin enthaltenden peptiden, die von filaggrin abstammen, zur behandlung von autoimmunkrankheiten Expired - Lifetime DE69813620T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9716672A FR2773078B1 (fr) 1997-12-30 1997-12-30 Utilisation de peptides citrullines derives de la filaggrine pour le traitement de la polyarthrite rhumatoide
FR9716672 1997-12-30
PCT/FR1998/002900 WO1999034819A2 (fr) 1997-12-30 1998-12-29 Utilisation de peptides citrullines derives de la filaggrine dans le cadre du traitement de maladies autoimmunes

Publications (2)

Publication Number Publication Date
DE69813620D1 true DE69813620D1 (de) 2003-05-22
DE69813620T2 DE69813620T2 (de) 2004-02-12

Family

ID=9515271

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69813620T Expired - Lifetime DE69813620T2 (de) 1997-12-30 1998-12-29 Verwendung von citrullin enthaltenden peptiden, die von filaggrin abstammen, zur behandlung von autoimmunkrankheiten

Country Status (10)

Country Link
EP (1) EP1041997B1 (de)
JP (1) JP4557421B2 (de)
AT (1) ATE237345T1 (de)
AU (1) AU1971899A (de)
CA (1) CA2315294C (de)
DE (1) DE69813620T2 (de)
DK (1) DK1041997T3 (de)
ES (1) ES2193601T3 (de)
FR (1) FR2773078B1 (de)
WO (1) WO1999034819A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2900657B1 (fr) * 2006-05-03 2009-04-17 Univ Toulouse Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
FR2908134B1 (fr) * 2007-12-04 2012-10-12 Univ Toulouse 3 Paul Sabatier Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011718A1 (en) * 1990-01-31 1991-08-08 Regents Of The Board Of The University Of Oklahoma Assays and treatments for autoimmune diseases
WO1992019649A1 (fr) * 1991-04-26 1992-11-12 Clonatec Antigenes reconnus par des anticorps de la polyarthrite rhumatoide, leur preparation et leurs applications
AU6098994A (en) * 1993-01-27 1994-08-15 Duke University Methods and agents for the diagnosis and treatment of rheumatoid arthritis
FR2752842B1 (fr) * 1996-08-30 1998-11-06 Biomerieux Sa Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide
NL1004539C2 (nl) * 1996-11-15 1998-05-20 Stichting Tech Wetenschapp Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen.
PL344534A1 (en) * 1997-11-28 2001-11-05 Innogenetics Nv Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
FR2773157B1 (fr) * 1997-12-30 2001-10-05 Bio Merieux Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide

Also Published As

Publication number Publication date
ES2193601T3 (es) 2003-11-01
CA2315294A1 (fr) 1999-07-15
JP4557421B2 (ja) 2010-10-06
JP2002500195A (ja) 2002-01-08
CA2315294C (fr) 2012-07-03
ATE237345T1 (de) 2003-05-15
DE69813620T2 (de) 2004-02-12
DK1041997T3 (da) 2003-08-04
EP1041997A2 (de) 2000-10-11
FR2773078A1 (fr) 1999-07-02
WO1999034819A2 (fr) 1999-07-15
FR2773078B1 (fr) 2000-05-26
AU1971899A (en) 1999-07-26
EP1041997B1 (de) 2003-04-16
WO1999034819A3 (fr) 1999-11-04

Similar Documents

Publication Publication Date Title
HUP0204199A2 (hu) Transzport vektorok
EP1194164A4 (de) Prion protein peptide und deren verwendung
BR9707819A (pt) Imunogenos peptidicos
BR0213786A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
ATE334694T1 (de) Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln
DE69533704D1 (de) Bradykinin-antagonist peptide mit n-substituierten glycinen
PT848720E (pt) Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros
NL300830I2 (nl) Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten
ATE227127T1 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
GB2367061A (en) Peptides
DE69534325D1 (de) Peptide zur behandlung von krebs
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
HUP9700676A2 (hu) Rekombináns anti-Fas antitestek és az ezeket kódoló DNS
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
GB9311454D0 (en) Pharmaceutical compositions
DE69813620D1 (de) Verwendung von citrullin enthaltenden peptiden, die von filaggrin abstammen, zur behandlung von autoimmunkrankheiten
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DE69819922D1 (de) 2-Amino-6-methyl-7-acetyl-tetralin und pharmazeutische Zusammensetzungen zur Vorbeugung und therapeutischen Behandlung von entzündlichen und/oder Autoimmunkrankheiten
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
ATE245438T1 (de) Verwendung von oligomerem matrixprotein aus knorpel zur behandlung von rheumatoider arthritis
SE9703287D0 (sv) Peptides

Legal Events

Date Code Title Description
8364 No opposition during term of opposition